Streetwise Reports' Article Archives — January 2021 back to current month (31)
Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.
Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.
KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report.
Avivagen Inc. reported it has secured a six tonne order for OxC-beta™ Livestock from a new customer in Queretaro City, Mexico.
Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.
Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.
iDocsWeb reported it formed a strategic partnership with Reliq Health Technologies to offer that firm's iUGO Remote Patient Monitoring, Chronic Care Management and Behavioral Health solutions platforms to its U.S. customers.
Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
Reliq Health Technologies launched a multilingual interactive voice recognition product called iUGO Care IVR and has contracted with a Maryland physician practice to offer the service to patients speaking Russian and English.
Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment."
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform.
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis.
ProMIS Neurosciences discusses its four priority areas in 2021.
Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease.
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector.
Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%.
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure.
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept?
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million.
Small-Cap Tech Stock Sees Huge Rise; What's Next? (01/07/2021)
Technical analyst Clive Maund charts Leonovus and discusses what could lie ahead for the stock after it gained 150%.
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report.
Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone.
Change Healthcare shares rose to a new 52-week high after the company reported it will be combining its operations with UnitedHealth's OptumInsight in an all cash purchase transaction for $25.75 per share.
Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic.
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.
Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team.
Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus.
|"Momentum continues to build for VIV."|